Pcn23 Gemtuzumab Ozogamicin Plus Standard Chemotherapy Carries a Comparable Burden of Hospitalization Compared With Standard Chemotherapy Alone in Acute Myeloid Leukemia

Sikirica, Slaven; Russell-Smith, T. Alexander; Welch, Verna L; D'Amico, Paul; Benner, Rebecca J.

doi:10.1016/j.jval.2020.04.1529

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From a clinical perspective, patients treated with GO in addition to standard chemotherapy versus standard chemotherapy in the ALFA-0701 trial had significantly longer event-free survival and no differences in the mean number of hospitalizations and the length of hospital stay [ 35 , 40 ]. Therefore, the addition of GO may provide considerable clinical value at minimal cost to a health plan and carries a hospitalization burden comparable with standard induction therapy.…”

Section: Discussionmentioning

confidence: 99%

Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia

et al. 2020

View full text Add to dashboard Cite

Background Gemtuzumab ozogamicin (GO) was approved in 2017 in the US for the treatment of adults with newly diagnosed CD33-positive (CD33+) acute myeloid leukemia (AML), and adults and pediatric patients with CD33+ relapsed/ refractory (R/R) AML. Objective The aim of this study was to estimate the budgetary impact of introducing GO to a 1-million-member US health plan over a 5-year period. Methods We developed models to estimate the impact of introducing GO in combination with conventional induction chemotherapy or as monotherapy for newly diagnosed AML, and as monotherapy for R/R AML. Models were built using data on drug costs and treatment-related outcomes obtained from published clinical trials and other publicly available sources. Results were reported on a per member/per year and per member/per month (PMPM) basis. Results Base-case results of the newly diagnosed model indicated that the addition of GO in the combination setting reduced the overall budget of a 1-million-member health plan. The estimated net cost

show abstract

Section: Discussionmentioning

confidence: 99%